RELMADA THERAPEUTICS, INC. (RLMD) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$4.15

From 52W high−47.58%

Volume2.06M

Market cap$439.48M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$4.15

From 52W high

−47.58%

Volume

2.06M

Market cap

$439.48M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.6x

P/E (TTM)

—

RSI (14)

35.6

MomentumView details →

1D Return

−1.90%

YTD Return

−15.33%

SummaryUpdated Jun 1, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology company founded in 2004 and headquartered in Coral Gables, Florida. The company has evolved from focusing primarily on a single drug candidate for depression treatment to building a diversified pipeline of central nervous system therapies and other medical treatments. After going public in 2014, Relmada has undergone significant strategic pivots in recent years, including acquiring new product candidates and expanding beyond its original depression treatment focus following mixed clinical trial results.

Ask drillr about RELMADA THERAPEUTICS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−29.98%

ROA (TTM)

−28.27%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+58.56%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+45.28%

EBITDA YoY

—

MomentumView details →

1D Return

−1.90%

YTD Return

−15.33%

1Y Return

+167.31%

RSI (14)

35.6

vs 50D SMA

−16.35%

vs 200D SMA

−25.32%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

29.52x

Quick Ratio

29.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.11

EPS Surprise

44.87%

Beats (12Q)

6/12

Next Q EPS Est

−$0.15

Avg Surprise (4Q)

−180.05%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−61.93M

Op. CF (TTM)

−45.99M

Next earningsNov 12, 2026 →

Latest newsMore news →

Relmada Therapeutics announced it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, targeting an investigational new drug application filing by the end of 2026.44d ago

Similar companies

Prothena Corporation plcPRTA Kyverna Therapeutics, Inc.KYTX Cutia Therapeutics02487.HK Genfit S.A.GNFT Cabaletta Bio, Inc.CABA Opus Genetics, Inc.IRD Find similar companies →

Latest newsMore news →